Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio

Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio Proactive uses images sourced from Shutterstock Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved. Shares ...